Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Flurbiprofen (dl-Flurbiprofen) 是一种高效的,具有口服活性的非甾体抗炎化合物,有退热止痛活性, 常用于炎症性疾病的研究。它是一种非选择性的环氧合酶抑制剂,可研究结肠癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
100 mg | ¥ 415 | 现货 | ||
500 mg | ¥ 581 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 133 | 现货 |
产品描述 | Flurbiprofen (dl-Flurbiprofen) is an anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE. |
体外活性 | Flurbiprofen effectively inhibits the growth of various tumor cells in a dose-dependent manner and causes a noticeable change in the progression of cells through cell cycle stages in tumor cell lines derived from medulloblastoma and glioblastoma multiforme. Flurbiprofen reduces the number of cells in G1 and G2, and significantly increases their numbers in S phase, suggesting that, Flurbiprofen accelerates G1/S entry, and/or delays cell exit from S to G2/M stages. Flurbiprofen causes a minor change in the RNA level of different cyclins, there is a significant decrease in the level of cyclin B protein upon flurbiprofen treatment. [1] |
体内活性 | Flurbiprofen affords significant neuroprotection from ischemic injury as evidenced by reduction in cerebral infarct volume and neurobehavioral deficit. Flurbiprofen significantly reduces an early calcium dependent rise in levels of nitrite and MDA in ischemic brain regions of rats. Flurbiprofen also reduces the proteolytic products (SBDPs) caused by ischemic activation of calcium dependent protease calpain. [2] Flurbiprofen (5 mg/kg and 10 mg/kg) significantly attenuates brain ischemia/reperfusion injury in rats, as shown by a reduction in the infarct volume, neurological deficit scores and cell apoptosis. Flurbiprofen not only inhibits the expression of Bax protein and p-GSK-3β, but also increases the expression of Bcl-2 protein, the ratio of Bcl-2/Bax as well as the P-Akt level in rats. [3] |
别名 | 氟比洛芬, dl-Flurbiprofen |
分子量 | 244.26 |
分子式 | C15H13FO2 |
CAS No. | 5104-49-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 12.2 mg/mL (50 mM)
DMSO: 24.4 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 4.094 mL | 20.47 mL | 40.94 mL | 102.35 mL |
5 mM | 0.8188 mL | 4.094 mL | 8.188 mL | 20.47 mL | |
10 mM | 0.4094 mL | 2.047 mL | 4.094 mL | 10.235 mL | |
20 mM | 0.2047 mL | 1.0235 mL | 2.047 mL | 5.1175 mL | |
50 mM | 0.0819 mL | 0.4094 mL | 0.8188 mL | 2.047 mL | |
DMSO | 100 mM | 0.0409 mL | 0.2047 mL | 0.4094 mL | 1.0235 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Flurbiprofen 5104-49-4 Apoptosis Immunology/Inflammation Neuroscience COX MRP NSAID Cyclooxygenase rheumatoid anti-inflammatory nonsteroidal arthritis NSAIA agent Inhibitor osteoarthritis 氟比洛芬 dl-Flurbiprofen inhibit inhibitor